Home > Full Text Reviews > Drug Class Review: Alzheimer's Drugs:...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Cover of Drug Class Review: Alzheimer's Drugs

Drug Class Review: Alzheimer's Drugs

Final Report

Drug Class Reviews

Richard A Hansen, PhD, Gerald Gartlehner, MD, MPH, Daniel J Kaufer, MD, Kathleen N Lohr, PhD, and Tim Carey, MD, MPH.

RTI-UNC Evidence-based Practice Center, Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, 725 Airport Road, CB# 7590, Chapel Hill, NC 27599-7590. Tim Carey, MD, MPH, Director.
Portland (OR): Oregon Health & Science University; 2006 Jun.
Copyright and Permissions

Alzheimer's disease (AD), the most common adult form of dementia. Currently available pharmacologic therapies, including cholinesterase inhibitors (ChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists, are considered symptomatic treatments based on their ability to slow the clinical progression of symptoms across cognitive, behavioral, and functional domains. The purpose of this review is to help policy makers and clinicians make informed choices about the use of ChEIs and memantine in the treatment of AD. We compare the efficacy, effectiveness, and safety of donepezil, galantamine, rivastigmine, tacrine, and memantine in patients with mild to severe AD.

Oregon Evidence-based Practice Center, Oregon Health & Science University, Mark Helfand, MD, MPH, Director.

The funding source, the Center for Evidence-based Policy, is supported by 17 organizations, including 15 state Medicaid programs. These organizations selected the topic and had input into the Key Questions for this review. The content and conclusions of the review are entirely determined by the Evidence-based Practice Center researchers. The authors of this report have no financial interest in any company that makes or distributes the products reviewed in this report.

Suggested citation:

Hansen RA, Gartlehner G, Kaufer D, Lohr K, Carey T. Drug Class Review of Alzheimer's Drugs. Final Report. 2006 http://derp.ohsu.edu/about/final-products.cfm

The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports.

Copyright © 2006, Oregon Health & Science University, Portland, Oregon.

PMID: 20480924

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...